Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled …
L Paz-Ares, M Dvorkin, Y Chen, N Reinmuth, K Hotta… - The Lancet, 2019 - thelancet.com
Background Most patients with small-cell lung cancer (SCLC) have extensive-stage disease
at presentation, and prognosis remains poor. Recently, immunotherapy has demonstrated …
at presentation, and prognosis remains poor. Recently, immunotherapy has demonstrated …
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer …
JW Goldman, M Dvorkin, Y Chen, N Reinmuth… - The Lancet …, 2021 - thelancet.com
Background First-line durvalumab plus etoposide with either cisplatin or carboplatin
(platinum–etoposide) showed a significant improvement in overall survival versus platinum …
(platinum–etoposide) showed a significant improvement in overall survival versus platinum …
[HTML][HTML] Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival …
L Paz-Ares, Y Chen, N Reinmuth, K Hotta, D Trukhin… - ESMO open, 2022 - Elsevier
Background In the phase III CASPIAN study, first-line durvalumab in combination with
etoposide plus either cisplatin or carboplatin (EP) significantly improved overall survival …
etoposide plus either cisplatin or carboplatin (EP) significantly improved overall survival …
FDA approval summary: atezolizumab and durvalumab in combination with platinum‐based chemotherapy in extensive stage small cell lung cancer
L Mathieu, S Shah, L Pai‐Scherf, E Larkins… - The …, 2021 - academic.oup.com
Abstract The US Food and Drug Administration (FDA) granted approval to atezolizumab and
durvalumab in March of 2019 and 2020, respectively, for use in combination with …
durvalumab in March of 2019 and 2020, respectively, for use in combination with …
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised …
J Wang, C Zhou, W Yao, Q Wang, X Min… - The Lancet …, 2022 - thelancet.com
Background Extensive-stage small-cell lung cancer (ES-SCLC) is associated with poor
prognosis and treatment options are scarce. Immunotherapy has shown robust clinical …
prognosis and treatment options are scarce. Immunotherapy has shown robust clinical …
[HTML][HTML] Design and rationale for a phase III, randomized, placebo-controlled trial of durvalumab with or without tremelimumab after concurrent chemoradiotherapy for …
Abstract Limited-stage (LS) small-cell lung cancer (SCLC) remains an area of high unmet
medical need. The standard-of-care therapy comprises curative-intent platinum-based …
medical need. The standard-of-care therapy comprises curative-intent platinum-based …
Evolving role of immunotherapy in small cell lung cancer
ED Barrows, MJ Blackburn, SV Liu - Seminars in Cancer Biology, 2022 - Elsevier
Small cell lung cancer (SCLC) is a highly lethal subtype of lung cancer with a particularly
poor prognosis. For decades, the best available systemic therapy was platinum plus …
poor prognosis. For decades, the best available systemic therapy was platinum plus …
Comparison of first-line treatments for patients with extensive-stage small cell lung cancer: a systematic review and network meta-analysis
T Zhou, Z Zhang, F Luo, Y Zhao, X Hou, T Liu… - JAMA Network …, 2020 - jamanetwork.com
Importance Combinations of chemotherapy with immunotherapy or bevacizumab in first-line
treatments of extensive-stage small cell lung cancer (ES-SCLC) have been evaluated in …
treatments of extensive-stage small cell lung cancer (ES-SCLC) have been evaluated in …
Cost-effectiveness analysis of durvalumab plus chemotherapy in the first-line treatment of extensive-stage small cell lung cancer
D Ding, H Hu, S Li, Y Zhu, Y Shi, M Liao, J Liu… - Journal of the National …, 2021 - jnccn.org
Background: In the CASPIAN trial, durvalumab 1 chemotherapy demonstrated significant
improvements in overall survival compared with chemotherapy alone in patients with …
improvements in overall survival compared with chemotherapy alone in patients with …
[HTML][HTML] Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study
Background Immune checkpoint blockade (ICB) targeting programmed cell death protein 1
and cytotoxic T lymphocyte-associated protein 4 has achieved modest clinical activity as …
and cytotoxic T lymphocyte-associated protein 4 has achieved modest clinical activity as …